Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG7986) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Obinutuzumab Other Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inh Selective estrogen receptor degrader (SERD[2]) (GDC-0927/SRN-927, RG6047) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: xxx

Phase: xxx

Region: xxx

Molecule: xxx

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CH NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CH
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) EE NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) EE
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FI NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FI
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GE NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GE
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HK NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HK
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HU NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HU
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IE NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IE
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) LA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) LA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ME NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ME
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MX NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MX
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MY NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MY
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NV NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NV
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OK NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OK
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OR NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OR
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OR NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OR
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PT NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PT
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RI NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RI
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RO NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RO
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RS NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RS
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SD NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SD
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SG NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SG
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SI NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SI
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UT NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UT
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) VA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) VA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) WV NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) WV
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ZA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ZA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NJ NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NJ
NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab MA NCT02724878—Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab MA
NCT02724878—Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446), Paclitaxel NY NCT02716038—Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446), Paclitaxel NY
NCT02716038—Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AL NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AL
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) HU NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) HU
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IA NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IA
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) LA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) LA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02989584—A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02989584—A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OK NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OK
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OR NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OR
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) DC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) DC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) HI NCT03024216—Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) HI
NCT03024216—Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) CA NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) CA
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) ES NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) ES
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) GB NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) GB
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) IT NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab, FAP-IL2v FP (RG7461) IT
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
1 of 183 clinical trials
1-4 of 183 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
Results contain non-US trial information only.

Click "OK" if you wish to proceed.
CancelOK